nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—Masoprocol—IGF1R—bone cancer	0.047	0.767	CrCbGaD
L-DOPA—Aminosalicylic Acid—PTGS2—bone cancer	0.00636	0.104	CrCbGaD
L-DOPA—Mesalazine—PTGS2—bone cancer	0.00499	0.0814	CrCbGaD
L-DOPA—Phlebitis—Epirubicin—bone cancer	0.00379	0.00464	CcSEcCtD
L-DOPA—Flatulence—Cisplatin—bone cancer	0.00378	0.00462	CcSEcCtD
L-DOPA—Muscle spasms—Cisplatin—bone cancer	0.00369	0.0045	CcSEcCtD
L-DOPA—Vascular purpura—Epirubicin—bone cancer	0.00365	0.00447	CcSEcCtD
L-DOPA—Vision blurred—Cisplatin—bone cancer	0.00361	0.00442	CcSEcCtD
L-DOPA—Tremor—Cisplatin—bone cancer	0.00359	0.00439	CcSEcCtD
L-DOPA—Ill-defined disorder—Cisplatin—bone cancer	0.00356	0.00435	CcSEcCtD
L-DOPA—Anaemia—Cisplatin—bone cancer	0.00354	0.00433	CcSEcCtD
L-DOPA—Phlebitis—Doxorubicin—bone cancer	0.00351	0.00429	CcSEcCtD
L-DOPA—Hot flush—Epirubicin—bone cancer	0.00349	0.00427	CcSEcCtD
L-DOPA—Menopausal symptoms—Epirubicin—bone cancer	0.00346	0.00423	CcSEcCtD
L-DOPA—Malaise—Cisplatin—bone cancer	0.00346	0.00422	CcSEcCtD
L-DOPA—Leukopenia—Cisplatin—bone cancer	0.00343	0.00419	CcSEcCtD
L-DOPA—Dermatitis bullous—Epirubicin—bone cancer	0.00342	0.00418	CcSEcCtD
L-DOPA—Purpura—Epirubicin—bone cancer	0.00339	0.00415	CcSEcCtD
L-DOPA—Vascular purpura—Doxorubicin—bone cancer	0.00338	0.00413	CcSEcCtD
L-DOPA—Convulsion—Cisplatin—bone cancer	0.00332	0.00406	CcSEcCtD
L-DOPA—Ataxia—Methotrexate—bone cancer	0.00328	0.00401	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.00327	0.004	CcSEcCtD
L-DOPA—Pain in extremity—Epirubicin—bone cancer	0.00327	0.004	CcSEcCtD
L-DOPA—Diplopia—Epirubicin—bone cancer	0.00327	0.004	CcSEcCtD
L-DOPA—Anxiety—Cisplatin—bone cancer	0.00325	0.00397	CcSEcCtD
L-DOPA—Hot flush—Doxorubicin—bone cancer	0.00323	0.00395	CcSEcCtD
L-DOPA—Discomfort—Cisplatin—bone cancer	0.00322	0.00394	CcSEcCtD
L-DOPA—Menopausal symptoms—Doxorubicin—bone cancer	0.00321	0.00392	CcSEcCtD
L-DOPA—Dermatitis bullous—Doxorubicin—bone cancer	0.00316	0.00387	CcSEcCtD
L-DOPA—Purpura—Doxorubicin—bone cancer	0.00314	0.00384	CcSEcCtD
L-DOPA—Oedema—Cisplatin—bone cancer	0.00313	0.00382	CcSEcCtD
L-DOPA—Ataxia—Epirubicin—bone cancer	0.00307	0.00376	CcSEcCtD
L-DOPA—Thrombocytopenia—Cisplatin—bone cancer	0.00306	0.00374	CcSEcCtD
L-DOPA—Blood creatinine increased—Epirubicin—bone cancer	0.00306	0.00374	CcSEcCtD
L-DOPA—Diplopia—Doxorubicin—bone cancer	0.00302	0.0037	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.00302	0.0037	CcSEcCtD
L-DOPA—Pain in extremity—Doxorubicin—bone cancer	0.00302	0.0037	CcSEcCtD
L-DOPA—Hyperhidrosis—Cisplatin—bone cancer	0.00302	0.0037	CcSEcCtD
L-DOPA—Orthostatic hypotension—Epirubicin—bone cancer	0.00299	0.00365	CcSEcCtD
L-DOPA—Anorexia—Cisplatin—bone cancer	0.00298	0.00364	CcSEcCtD
L-DOPA—Epinephrine—CYP3A4—bone cancer	0.00294	0.0479	CrCbGaD
L-DOPA—Hypotension—Cisplatin—bone cancer	0.00292	0.00357	CcSEcCtD
L-DOPA—Nasopharyngitis—Epirubicin—bone cancer	0.00292	0.00357	CcSEcCtD
L-DOPA—Gastritis—Epirubicin—bone cancer	0.00289	0.00354	CcSEcCtD
L-DOPA—Ataxia—Doxorubicin—bone cancer	0.00284	0.00348	CcSEcCtD
L-DOPA—Blood creatinine increased—Doxorubicin—bone cancer	0.00283	0.00346	CcSEcCtD
L-DOPA—Dysphagia—Epirubicin—bone cancer	0.00283	0.00345	CcSEcCtD
L-DOPA—Paraesthesia—Cisplatin—bone cancer	0.00281	0.00343	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Methotrexate—bone cancer	0.00281	0.00343	CcSEcCtD
L-DOPA—Dyspnoea—Cisplatin—bone cancer	0.00279	0.00341	CcSEcCtD
L-DOPA—Orthostatic hypotension—Doxorubicin—bone cancer	0.00276	0.00338	CcSEcCtD
L-DOPA—Angina pectoris—Epirubicin—bone cancer	0.00275	0.00336	CcSEcCtD
L-DOPA—Decreased appetite—Cisplatin—bone cancer	0.00272	0.00332	CcSEcCtD
L-DOPA—Nasopharyngitis—Doxorubicin—bone cancer	0.0027	0.00331	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Cisplatin—bone cancer	0.0027	0.0033	CcSEcCtD
L-DOPA—Depression—Methotrexate—bone cancer	0.00268	0.00328	CcSEcCtD
L-DOPA—Gastritis—Doxorubicin—bone cancer	0.00268	0.00327	CcSEcCtD
L-DOPA—Pain—Cisplatin—bone cancer	0.00268	0.00327	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Epirubicin—bone cancer	0.00263	0.00321	CcSEcCtD
L-DOPA—Dysphagia—Doxorubicin—bone cancer	0.00261	0.00319	CcSEcCtD
L-DOPA—Pollakiuria—Epirubicin—bone cancer	0.00261	0.00319	CcSEcCtD
L-DOPA—Feeling abnormal—Cisplatin—bone cancer	0.00258	0.00315	CcSEcCtD
L-DOPA—Weight increased—Epirubicin—bone cancer	0.00257	0.00314	CcSEcCtD
L-DOPA—Weight decreased—Epirubicin—bone cancer	0.00256	0.00312	CcSEcCtD
L-DOPA—Angina pectoris—Doxorubicin—bone cancer	0.00255	0.00311	CcSEcCtD
L-DOPA—Agranulocytosis—Methotrexate—bone cancer	0.00251	0.00307	CcSEcCtD
L-DOPA—Neuropathy peripheral—Epirubicin—bone cancer	0.00247	0.00302	CcSEcCtD
L-DOPA—Urinary tract infection—Epirubicin—bone cancer	0.00245	0.00299	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Doxorubicin—bone cancer	0.00243	0.00297	CcSEcCtD
L-DOPA—Haemoglobin—Methotrexate—bone cancer	0.00243	0.00297	CcSEcCtD
L-DOPA—Haemorrhage—Methotrexate—bone cancer	0.00242	0.00295	CcSEcCtD
L-DOPA—Pollakiuria—Doxorubicin—bone cancer	0.00241	0.00295	CcSEcCtD
L-DOPA—Urinary tract disorder—Methotrexate—bone cancer	0.00239	0.00292	CcSEcCtD
L-DOPA—Weight increased—Doxorubicin—bone cancer	0.00238	0.00291	CcSEcCtD
L-DOPA—Urethral disorder—Methotrexate—bone cancer	0.00237	0.0029	CcSEcCtD
L-DOPA—Weight decreased—Doxorubicin—bone cancer	0.00236	0.00289	CcSEcCtD
L-DOPA—Agranulocytosis—Epirubicin—bone cancer	0.00235	0.00287	CcSEcCtD
L-DOPA—Hypersensitivity—Cisplatin—bone cancer	0.0023	0.00282	CcSEcCtD
L-DOPA—Neuropathy peripheral—Doxorubicin—bone cancer	0.00228	0.00279	CcSEcCtD
L-DOPA—Haemoglobin—Epirubicin—bone cancer	0.00227	0.00278	CcSEcCtD
L-DOPA—Rhinitis—Epirubicin—bone cancer	0.00227	0.00277	CcSEcCtD
L-DOPA—Urinary tract infection—Doxorubicin—bone cancer	0.00227	0.00277	CcSEcCtD
L-DOPA—Haemorrhage—Epirubicin—bone cancer	0.00226	0.00276	CcSEcCtD
L-DOPA—Hypoaesthesia—Epirubicin—bone cancer	0.00225	0.00275	CcSEcCtD
L-DOPA—Asthenia—Cisplatin—bone cancer	0.00224	0.00274	CcSEcCtD
L-DOPA—Urinary tract disorder—Epirubicin—bone cancer	0.00223	0.00273	CcSEcCtD
L-DOPA—Urethral disorder—Epirubicin—bone cancer	0.00222	0.00271	CcSEcCtD
L-DOPA—Agranulocytosis—Doxorubicin—bone cancer	0.00218	0.00266	CcSEcCtD
L-DOPA—Diarrhoea—Cisplatin—bone cancer	0.00214	0.00262	CcSEcCtD
L-DOPA—Alopecia—Methotrexate—bone cancer	0.00214	0.00261	CcSEcCtD
L-DOPA—Mental disorder—Methotrexate—bone cancer	0.00212	0.00259	CcSEcCtD
L-DOPA—Haemoglobin—Doxorubicin—bone cancer	0.0021	0.00257	CcSEcCtD
L-DOPA—Flushing—Epirubicin—bone cancer	0.0021	0.00257	CcSEcCtD
L-DOPA—Rhinitis—Doxorubicin—bone cancer	0.0021	0.00256	CcSEcCtD
L-DOPA—Haemorrhage—Doxorubicin—bone cancer	0.00209	0.00256	CcSEcCtD
L-DOPA—Hypoaesthesia—Doxorubicin—bone cancer	0.00208	0.00254	CcSEcCtD
L-DOPA—Urinary tract disorder—Doxorubicin—bone cancer	0.00207	0.00253	CcSEcCtD
L-DOPA—Dysgeusia—Methotrexate—bone cancer	0.00206	0.00252	CcSEcCtD
L-DOPA—Urethral disorder—Doxorubicin—bone cancer	0.00205	0.00251	CcSEcCtD
L-DOPA—Back pain—Methotrexate—bone cancer	0.00203	0.00249	CcSEcCtD
L-DOPA—Arrhythmia—Epirubicin—bone cancer	0.00202	0.00247	CcSEcCtD
L-DOPA—Alopecia—Epirubicin—bone cancer	0.002	0.00244	CcSEcCtD
L-DOPA—Vomiting—Cisplatin—bone cancer	0.00199	0.00243	CcSEcCtD
L-DOPA—Vision blurred—Methotrexate—bone cancer	0.00198	0.00242	CcSEcCtD
L-DOPA—Mental disorder—Epirubicin—bone cancer	0.00198	0.00242	CcSEcCtD
L-DOPA—Rash—Cisplatin—bone cancer	0.00197	0.00241	CcSEcCtD
L-DOPA—Dermatitis—Cisplatin—bone cancer	0.00197	0.00241	CcSEcCtD
L-DOPA—Ill-defined disorder—Methotrexate—bone cancer	0.00195	0.00239	CcSEcCtD
L-DOPA—Anaemia—Methotrexate—bone cancer	0.00194	0.00238	CcSEcCtD
L-DOPA—Flushing—Doxorubicin—bone cancer	0.00194	0.00237	CcSEcCtD
L-DOPA—Flatulence—Epirubicin—bone cancer	0.00194	0.00237	CcSEcCtD
L-DOPA—Tension—Epirubicin—bone cancer	0.00193	0.00236	CcSEcCtD
L-DOPA—Dysgeusia—Epirubicin—bone cancer	0.00193	0.00236	CcSEcCtD
L-DOPA—Nervousness—Epirubicin—bone cancer	0.00191	0.00234	CcSEcCtD
L-DOPA—Back pain—Epirubicin—bone cancer	0.0019	0.00233	CcSEcCtD
L-DOPA—Malaise—Methotrexate—bone cancer	0.0019	0.00232	CcSEcCtD
L-DOPA—Muscle spasms—Epirubicin—bone cancer	0.00189	0.00231	CcSEcCtD
L-DOPA—DRD4—GPCRs, Other—GRM1—bone cancer	0.00189	0.0157	CbGpPWpGaD
L-DOPA—Leukopenia—Methotrexate—bone cancer	0.00188	0.0023	CcSEcCtD
L-DOPA—Arrhythmia—Doxorubicin—bone cancer	0.00187	0.00228	CcSEcCtD
L-DOPA—Nausea—Cisplatin—bone cancer	0.00186	0.00227	CcSEcCtD
L-DOPA—Vision blurred—Epirubicin—bone cancer	0.00186	0.00227	CcSEcCtD
L-DOPA—Alopecia—Doxorubicin—bone cancer	0.00185	0.00226	CcSEcCtD
L-DOPA—SLC7A5—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.00184	0.0152	CbGpPWpGaD
L-DOPA—Cough—Methotrexate—bone cancer	0.00184	0.00224	CcSEcCtD
L-DOPA—Mental disorder—Doxorubicin—bone cancer	0.00183	0.00224	CcSEcCtD
L-DOPA—Ill-defined disorder—Epirubicin—bone cancer	0.00183	0.00223	CcSEcCtD
L-DOPA—Convulsion—Methotrexate—bone cancer	0.00182	0.00223	CcSEcCtD
L-DOPA—Anaemia—Epirubicin—bone cancer	0.00182	0.00222	CcSEcCtD
L-DOPA—Agitation—Epirubicin—bone cancer	0.00181	0.00221	CcSEcCtD
L-DOPA—Flatulence—Doxorubicin—bone cancer	0.00179	0.00219	CcSEcCtD
L-DOPA—Chest pain—Methotrexate—bone cancer	0.00179	0.00219	CcSEcCtD
L-DOPA—Tension—Doxorubicin—bone cancer	0.00179	0.00218	CcSEcCtD
L-DOPA—Dysgeusia—Doxorubicin—bone cancer	0.00178	0.00218	CcSEcCtD
L-DOPA—Malaise—Epirubicin—bone cancer	0.00178	0.00217	CcSEcCtD
L-DOPA—Discomfort—Methotrexate—bone cancer	0.00177	0.00216	CcSEcCtD
L-DOPA—Nervousness—Doxorubicin—bone cancer	0.00177	0.00216	CcSEcCtD
L-DOPA—Syncope—Epirubicin—bone cancer	0.00177	0.00216	CcSEcCtD
L-DOPA—Leukopenia—Epirubicin—bone cancer	0.00176	0.00215	CcSEcCtD
L-DOPA—Back pain—Doxorubicin—bone cancer	0.00176	0.00215	CcSEcCtD
L-DOPA—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00176	0.0146	CbGpPWpGaD
L-DOPA—Muscle spasms—Doxorubicin—bone cancer	0.00175	0.00214	CcSEcCtD
L-DOPA—Palpitations—Epirubicin—bone cancer	0.00174	0.00213	CcSEcCtD
L-DOPA—Confusional state—Methotrexate—bone cancer	0.00173	0.00212	CcSEcCtD
L-DOPA—Loss of consciousness—Epirubicin—bone cancer	0.00173	0.00211	CcSEcCtD
L-DOPA—DRD1—Circadian rythm related genes—TNFRSF11A—bone cancer	0.00172	0.0143	CbGpPWpGaD
L-DOPA—Cough—Epirubicin—bone cancer	0.00172	0.0021	CcSEcCtD
L-DOPA—Vision blurred—Doxorubicin—bone cancer	0.00172	0.0021	CcSEcCtD
L-DOPA—Convulsion—Epirubicin—bone cancer	0.00171	0.00208	CcSEcCtD
L-DOPA—Hypertension—Epirubicin—bone cancer	0.0017	0.00208	CcSEcCtD
L-DOPA—DRD3—Circadian rythm related genes—TNFRSF11A—bone cancer	0.0017	0.0141	CbGpPWpGaD
L-DOPA—Ill-defined disorder—Doxorubicin—bone cancer	0.00169	0.00207	CcSEcCtD
L-DOPA—Anaemia—Doxorubicin—bone cancer	0.00168	0.00206	CcSEcCtD
L-DOPA—Thrombocytopenia—Methotrexate—bone cancer	0.00168	0.00205	CcSEcCtD
L-DOPA—DRD3—GPCRs, Other—GRM1—bone cancer	0.00168	0.0139	CbGpPWpGaD
L-DOPA—Chest pain—Epirubicin—bone cancer	0.00168	0.00205	CcSEcCtD
L-DOPA—Agitation—Doxorubicin—bone cancer	0.00167	0.00205	CcSEcCtD
L-DOPA—Anxiety—Epirubicin—bone cancer	0.00167	0.00204	CcSEcCtD
L-DOPA—Hyperhidrosis—Methotrexate—bone cancer	0.00166	0.00203	CcSEcCtD
L-DOPA—Discomfort—Epirubicin—bone cancer	0.00166	0.00202	CcSEcCtD
L-DOPA—Malaise—Doxorubicin—bone cancer	0.00164	0.00201	CcSEcCtD
L-DOPA—Dry mouth—Epirubicin—bone cancer	0.00164	0.002	CcSEcCtD
L-DOPA—Anorexia—Methotrexate—bone cancer	0.00164	0.002	CcSEcCtD
L-DOPA—Syncope—Doxorubicin—bone cancer	0.00163	0.002	CcSEcCtD
L-DOPA—Leukopenia—Doxorubicin—bone cancer	0.00163	0.00199	CcSEcCtD
L-DOPA—Confusional state—Epirubicin—bone cancer	0.00162	0.00198	CcSEcCtD
L-DOPA—Palpitations—Doxorubicin—bone cancer	0.00161	0.00197	CcSEcCtD
L-DOPA—Oedema—Epirubicin—bone cancer	0.00161	0.00196	CcSEcCtD
L-DOPA—Hypotension—Methotrexate—bone cancer	0.0016	0.00196	CcSEcCtD
L-DOPA—Loss of consciousness—Doxorubicin—bone cancer	0.0016	0.00196	CcSEcCtD
L-DOPA—Cough—Doxorubicin—bone cancer	0.00159	0.00194	CcSEcCtD
L-DOPA—Shock—Epirubicin—bone cancer	0.00158	0.00193	CcSEcCtD
L-DOPA—Convulsion—Doxorubicin—bone cancer	0.00158	0.00193	CcSEcCtD
L-DOPA—Thrombocytopenia—Epirubicin—bone cancer	0.00157	0.00192	CcSEcCtD
L-DOPA—Hypertension—Doxorubicin—bone cancer	0.00157	0.00192	CcSEcCtD
L-DOPA—Hyperhidrosis—Epirubicin—bone cancer	0.00155	0.0019	CcSEcCtD
L-DOPA—Insomnia—Methotrexate—bone cancer	0.00155	0.0019	CcSEcCtD
L-DOPA—Chest pain—Doxorubicin—bone cancer	0.00155	0.0019	CcSEcCtD
L-DOPA—Anxiety—Doxorubicin—bone cancer	0.00155	0.00189	CcSEcCtD
L-DOPA—Paraesthesia—Methotrexate—bone cancer	0.00154	0.00188	CcSEcCtD
L-DOPA—Discomfort—Doxorubicin—bone cancer	0.00153	0.00187	CcSEcCtD
L-DOPA—Anorexia—Epirubicin—bone cancer	0.00153	0.00187	CcSEcCtD
L-DOPA—Dyspnoea—Methotrexate—bone cancer	0.00153	0.00187	CcSEcCtD
L-DOPA—Somnolence—Methotrexate—bone cancer	0.00153	0.00187	CcSEcCtD
L-DOPA—Dry mouth—Doxorubicin—bone cancer	0.00152	0.00185	CcSEcCtD
L-DOPA—DDC—Tryptophan metabolism—MDM2—bone cancer	0.00151	0.0125	CbGpPWpGaD
L-DOPA—Dyspepsia—Methotrexate—bone cancer	0.00151	0.00185	CcSEcCtD
L-DOPA—Hypotension—Epirubicin—bone cancer	0.0015	0.00183	CcSEcCtD
L-DOPA—Confusional state—Doxorubicin—bone cancer	0.0015	0.00183	CcSEcCtD
L-DOPA—Decreased appetite—Methotrexate—bone cancer	0.00149	0.00182	CcSEcCtD
L-DOPA—Oedema—Doxorubicin—bone cancer	0.00149	0.00182	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Methotrexate—bone cancer	0.00148	0.00181	CcSEcCtD
L-DOPA—Fatigue—Methotrexate—bone cancer	0.00148	0.00181	CcSEcCtD
L-DOPA—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.00147	0.0122	CbGpPWpGaD
L-DOPA—Pain—Methotrexate—bone cancer	0.00147	0.00179	CcSEcCtD
L-DOPA—Shock—Doxorubicin—bone cancer	0.00146	0.00179	CcSEcCtD
L-DOPA—Thrombocytopenia—Doxorubicin—bone cancer	0.00146	0.00178	CcSEcCtD
L-DOPA—Insomnia—Epirubicin—bone cancer	0.00145	0.00178	CcSEcCtD
L-DOPA—SLC7A5—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.00144	0.012	CbGpPWpGaD
L-DOPA—Paraesthesia—Epirubicin—bone cancer	0.00144	0.00176	CcSEcCtD
L-DOPA—Hyperhidrosis—Doxorubicin—bone cancer	0.00144	0.00176	CcSEcCtD
L-DOPA—Dyspnoea—Epirubicin—bone cancer	0.00143	0.00175	CcSEcCtD
L-DOPA—Somnolence—Epirubicin—bone cancer	0.00143	0.00175	CcSEcCtD
L-DOPA—Anorexia—Doxorubicin—bone cancer	0.00142	0.00173	CcSEcCtD
L-DOPA—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.00142	0.0117	CbGpPWpGaD
L-DOPA—Feeling abnormal—Methotrexate—bone cancer	0.00141	0.00173	CcSEcCtD
L-DOPA—Dyspepsia—Epirubicin—bone cancer	0.00141	0.00173	CcSEcCtD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00141	0.0117	CbGpPWpGaD
L-DOPA—Gastrointestinal pain—Methotrexate—bone cancer	0.0014	0.00172	CcSEcCtD
L-DOPA—Decreased appetite—Epirubicin—bone cancer	0.0014	0.00171	CcSEcCtD
L-DOPA—Hypotension—Doxorubicin—bone cancer	0.00139	0.0017	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Epirubicin—bone cancer	0.00139	0.0017	CcSEcCtD
L-DOPA—Fatigue—Epirubicin—bone cancer	0.00139	0.00169	CcSEcCtD
L-DOPA—Constipation—Epirubicin—bone cancer	0.00137	0.00168	CcSEcCtD
L-DOPA—Pain—Epirubicin—bone cancer	0.00137	0.00168	CcSEcCtD
L-DOPA—Urticaria—Methotrexate—bone cancer	0.00136	0.00167	CcSEcCtD
L-DOPA—Abdominal pain—Methotrexate—bone cancer	0.00136	0.00166	CcSEcCtD
L-DOPA—Insomnia—Doxorubicin—bone cancer	0.00134	0.00164	CcSEcCtD
L-DOPA—Paraesthesia—Doxorubicin—bone cancer	0.00133	0.00163	CcSEcCtD
L-DOPA—DRD4—GPCRs, Other—SMO—bone cancer	0.00133	0.0111	CbGpPWpGaD
L-DOPA—Dyspnoea—Doxorubicin—bone cancer	0.00133	0.00162	CcSEcCtD
L-DOPA—Feeling abnormal—Epirubicin—bone cancer	0.00132	0.00162	CcSEcCtD
L-DOPA—Somnolence—Doxorubicin—bone cancer	0.00132	0.00162	CcSEcCtD
L-DOPA—Gastrointestinal pain—Epirubicin—bone cancer	0.00131	0.00161	CcSEcCtD
L-DOPA—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.00131	0.0109	CbGpPWpGaD
L-DOPA—Dyspepsia—Doxorubicin—bone cancer	0.00131	0.0016	CcSEcCtD
L-DOPA—DRD2—Circadian rythm related genes—TNFRSF11A—bone cancer	0.0013	0.0108	CbGpPWpGaD
L-DOPA—Decreased appetite—Doxorubicin—bone cancer	0.00129	0.00158	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00128	0.00157	CcSEcCtD
L-DOPA—Fatigue—Doxorubicin—bone cancer	0.00128	0.00157	CcSEcCtD
L-DOPA—Urticaria—Epirubicin—bone cancer	0.00128	0.00156	CcSEcCtD
L-DOPA—Constipation—Doxorubicin—bone cancer	0.00127	0.00155	CcSEcCtD
L-DOPA—Pain—Doxorubicin—bone cancer	0.00127	0.00155	CcSEcCtD
L-DOPA—Abdominal pain—Epirubicin—bone cancer	0.00127	0.00155	CcSEcCtD
L-DOPA—Hypersensitivity—Methotrexate—bone cancer	0.00126	0.00155	CcSEcCtD
L-DOPA—Asthenia—Methotrexate—bone cancer	0.00123	0.00151	CcSEcCtD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00123	0.0102	CbGpPWpGaD
L-DOPA—Feeling abnormal—Doxorubicin—bone cancer	0.00122	0.0015	CcSEcCtD
L-DOPA—Gastrointestinal pain—Doxorubicin—bone cancer	0.00122	0.00149	CcSEcCtD
L-DOPA—Pruritus—Methotrexate—bone cancer	0.00121	0.00148	CcSEcCtD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00121	0.0101	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Other—SMO—bone cancer	0.00118	0.00982	CbGpPWpGaD
L-DOPA—Hypersensitivity—Epirubicin—bone cancer	0.00118	0.00145	CcSEcCtD
L-DOPA—Urticaria—Doxorubicin—bone cancer	0.00118	0.00144	CcSEcCtD
L-DOPA—Abdominal pain—Doxorubicin—bone cancer	0.00118	0.00144	CcSEcCtD
L-DOPA—Diarrhoea—Methotrexate—bone cancer	0.00117	0.00144	CcSEcCtD
L-DOPA—Asthenia—Epirubicin—bone cancer	0.00115	0.00141	CcSEcCtD
L-DOPA—Pruritus—Epirubicin—bone cancer	0.00114	0.00139	CcSEcCtD
L-DOPA—Dizziness—Methotrexate—bone cancer	0.00114	0.00139	CcSEcCtD
L-DOPA—DDC—Circadian rythm related genes—GNA11—bone cancer	0.00111	0.00925	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—EZH2—bone cancer	0.00111	0.00921	CbGpPWpGaD
L-DOPA—Diarrhoea—Epirubicin—bone cancer	0.0011	0.00134	CcSEcCtD
L-DOPA—Hypersensitivity—Doxorubicin—bone cancer	0.0011	0.00134	CcSEcCtD
L-DOPA—Vomiting—Methotrexate—bone cancer	0.00109	0.00133	CcSEcCtD
L-DOPA—Rash—Methotrexate—bone cancer	0.00108	0.00132	CcSEcCtD
L-DOPA—Dermatitis—Methotrexate—bone cancer	0.00108	0.00132	CcSEcCtD
L-DOPA—Headache—Methotrexate—bone cancer	0.00108	0.00131	CcSEcCtD
L-DOPA—Asthenia—Doxorubicin—bone cancer	0.00107	0.0013	CcSEcCtD
L-DOPA—Dizziness—Epirubicin—bone cancer	0.00106	0.0013	CcSEcCtD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00106	0.00879	CbGpPWpGaD
L-DOPA—Pruritus—Doxorubicin—bone cancer	0.00105	0.00129	CcSEcCtD
L-DOPA—Vomiting—Epirubicin—bone cancer	0.00102	0.00125	CcSEcCtD
L-DOPA—DRD4—G alpha (i) signalling events—GRM4—bone cancer	0.00102	0.00847	CbGpPWpGaD
L-DOPA—DRD4—G alpha (i) signalling events—RGS1—bone cancer	0.00102	0.00847	CbGpPWpGaD
L-DOPA—Nausea—Methotrexate—bone cancer	0.00102	0.00125	CcSEcCtD
L-DOPA—Diarrhoea—Doxorubicin—bone cancer	0.00102	0.00124	CcSEcCtD
L-DOPA—Rash—Epirubicin—bone cancer	0.00101	0.00124	CcSEcCtD
L-DOPA—Dermatitis—Epirubicin—bone cancer	0.00101	0.00124	CcSEcCtD
L-DOPA—Headache—Epirubicin—bone cancer	0.00101	0.00123	CcSEcCtD
L-DOPA—Dizziness—Doxorubicin—bone cancer	0.000983	0.0012	CcSEcCtD
L-DOPA—Nausea—Epirubicin—bone cancer	0.000954	0.00117	CcSEcCtD
L-DOPA—Vomiting—Doxorubicin—bone cancer	0.000945	0.00116	CcSEcCtD
L-DOPA—Rash—Doxorubicin—bone cancer	0.000937	0.00115	CcSEcCtD
L-DOPA—Dermatitis—Doxorubicin—bone cancer	0.000936	0.00114	CcSEcCtD
L-DOPA—SLC7A8—Hemostasis—SPARC—bone cancer	0.000933	0.00774	CbGpPWpGaD
L-DOPA—Headache—Doxorubicin—bone cancer	0.000931	0.00114	CcSEcCtD
L-DOPA—DRD3—G alpha (i) signalling events—RGS1—bone cancer	0.000907	0.00752	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—GRM4—bone cancer	0.000907	0.00752	CbGpPWpGaD
L-DOPA—Nausea—Doxorubicin—bone cancer	0.000883	0.00108	CcSEcCtD
L-DOPA—SLC7A8—Hemostasis—GNA11—bone cancer	0.000854	0.00708	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—GRM4—bone cancer	0.000838	0.00695	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000816	0.00676	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—SPARC—bone cancer	0.000814	0.00675	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—IL3—bone cancer	0.000774	0.00642	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—GNA11—bone cancer	0.000745	0.00618	CbGpPWpGaD
L-DOPA—PSIP1—Disease—ENO2—bone cancer	0.000731	0.00606	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—GRM1—bone cancer	0.000726	0.00602	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000704	0.00584	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—GRM4—bone cancer	0.000694	0.00576	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—RGS1—bone cancer	0.000694	0.00576	CbGpPWpGaD
L-DOPA—DDC—Metabolism—NDUFA12—bone cancer	0.000686	0.00569	CbGpPWpGaD
L-DOPA—PSIP1—Disease—DHFR—bone cancer	0.000678	0.00562	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—IL3—bone cancer	0.000675	0.0056	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—GNA11—bone cancer	0.000647	0.00536	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—EZH2—bone cancer	0.000644	0.00534	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000634	0.00525	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—CDK4—bone cancer	0.000627	0.0052	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—GRM4—bone cancer	0.000618	0.00513	CbGpPWpGaD
L-DOPA—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000611	0.00507	CbGpPWpGaD
L-DOPA—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000603	0.005	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—GNA11—bone cancer	0.000582	0.00483	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—EZH2—bone cancer	0.00058	0.00481	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—GNA11—bone cancer	0.000574	0.00476	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—EZH2—bone cancer	0.000572	0.00474	CbGpPWpGaD
L-DOPA—DDC—Metabolism—NT5C3A—bone cancer	0.000569	0.00472	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—GRM4—bone cancer	0.000557	0.00462	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—GRM4—bone cancer	0.000549	0.00456	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000547	0.00454	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—GRM1—bone cancer	0.000536	0.00445	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—SMO—bone cancer	0.000512	0.00424	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—PLAU—bone cancer	0.000508	0.00421	CbGpPWpGaD
L-DOPA—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000496	0.00411	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—JUN—bone cancer	0.000495	0.0041	CbGpPWpGaD
L-DOPA—PSIP1—Disease—TGFBR2—bone cancer	0.000491	0.00407	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—GRM1—bone cancer	0.000483	0.004	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—GRM1—bone cancer	0.000476	0.00395	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—RGS1—bone cancer	0.000473	0.00393	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—GRM4—bone cancer	0.000473	0.00393	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—PLAU—bone cancer	0.000443	0.00367	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—GNA11—bone cancer	0.000439	0.00365	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—EZH2—bone cancer	0.000438	0.00363	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—GRM4—bone cancer	0.00043	0.00357	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—RGS1—bone cancer	0.00043	0.00357	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—GRM4—bone cancer	0.00042	0.00349	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—GRM1—bone cancer	0.000411	0.0034	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—JUN—bone cancer	0.000404	0.00335	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—SMO—bone cancer	0.000378	0.00313	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—GRM1—bone cancer	0.000373	0.00309	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—GRM1—bone cancer	0.000364	0.00302	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—CDK4—bone cancer	0.000363	0.00301	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—RGS1—bone cancer	0.000349	0.0029	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—GRM4—bone cancer	0.000349	0.0029	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—SMO—bone cancer	0.00034	0.00282	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—SMO—bone cancer	0.000336	0.00278	CbGpPWpGaD
L-DOPA—PSIP1—Disease—KIT—bone cancer	0.000335	0.00278	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—CDK4—bone cancer	0.000327	0.00271	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—CDK4—bone cancer	0.000323	0.00268	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—RGS1—bone cancer	0.000317	0.00263	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—GRM4—bone cancer	0.000317	0.00263	CbGpPWpGaD
L-DOPA—PSIP1—Disease—BRAF—bone cancer	0.000315	0.00261	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—GRM4—bone cancer	0.000315	0.00261	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—RGS1—bone cancer	0.000315	0.00261	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—GRM4—bone cancer	0.00031	0.00257	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—RGS1—bone cancer	0.00031	0.00257	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—GRM1—bone cancer	0.000303	0.00251	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—GRM4—bone cancer	0.000286	0.00237	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—RGS1—bone cancer	0.000286	0.00237	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—GRM4—bone cancer	0.000282	0.00234	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—RGS1—bone cancer	0.000282	0.00234	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—GRM1—bone cancer	0.000275	0.00228	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—GRM1—bone cancer	0.000273	0.00226	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—GRM1—bone cancer	0.000269	0.00223	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—TP53—bone cancer	0.000267	0.00221	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—GNA11—bone cancer	0.000265	0.00219	CbGpPWpGaD
L-DOPA—PSIP1—Disease—MDM2—bone cancer	0.000264	0.00219	CbGpPWpGaD
L-DOPA—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000263	0.00218	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—SMO—bone cancer	0.000263	0.00218	CbGpPWpGaD
L-DOPA—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.00026	0.00215	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—SMO—bone cancer	0.000257	0.00213	CbGpPWpGaD
L-DOPA—PSIP1—Disease—PTGS2—bone cancer	0.000254	0.00211	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—GRM4—bone cancer	0.000254	0.00211	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RGS1—bone cancer	0.000254	0.00211	CbGpPWpGaD
L-DOPA—DDC—Metabolism—ENO2—bone cancer	0.000249	0.00207	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—GRM1—bone cancer	0.000248	0.00205	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—CDK4—bone cancer	0.000247	0.00205	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—GRM1—bone cancer	0.000244	0.00203	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—GNA11—bone cancer	0.00024	0.00199	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—IL3—bone cancer	0.00024	0.00199	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—GRM4—bone cancer	0.000238	0.00197	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—RGS1—bone cancer	0.000238	0.00197	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—JUN—bone cancer	0.000234	0.00194	CbGpPWpGaD
L-DOPA—DDC—Metabolism—DHFR—bone cancer	0.000231	0.00192	CbGpPWpGaD
L-DOPA—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000225	0.00187	CbGpPWpGaD
L-DOPA—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000222	0.00184	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—GRM1—bone cancer	0.00022	0.00183	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL3—bone cancer	0.000218	0.00181	CbGpPWpGaD
L-DOPA—DDC—Metabolism—GNA11—bone cancer	0.000216	0.00179	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—RGS1—bone cancer	0.000216	0.00179	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—GRM4—bone cancer	0.000216	0.00179	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—JUN—bone cancer	0.000211	0.00175	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—JUN—bone cancer	0.000208	0.00173	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—GRM1—bone cancer	0.000206	0.00171	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—TP53—bone cancer	0.000204	0.00169	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CYP3A4—bone cancer	0.000196	0.00162	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—GNA11—bone cancer	0.000195	0.00162	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—SMO—bone cancer	0.000194	0.00161	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GRM4—bone cancer	0.000187	0.00155	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RGS1—bone cancer	0.000187	0.00155	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—GRM1—bone cancer	0.000187	0.00155	CbGpPWpGaD
L-DOPA—PSIP1—Disease—EGFR—bone cancer	0.00018	0.0015	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—TP53—bone cancer	0.000178	0.00148	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—GNA11—bone cancer	0.000177	0.00147	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—IL3—bone cancer	0.000177	0.00147	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—GNA11—bone cancer	0.000176	0.00146	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—SMO—bone cancer	0.000175	0.00145	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—GNA11—bone cancer	0.000173	0.00144	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—SMO—bone cancer	0.000172	0.00143	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RGS1—bone cancer	0.000169	0.0014	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GRM4—bone cancer	0.000169	0.0014	CbGpPWpGaD
L-DOPA—DDC—Metabolism—GSTP1—bone cancer	0.000167	0.00139	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RGS1—bone cancer	0.000167	0.00138	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GRM4—bone cancer	0.000167	0.00138	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GRM1—bone cancer	0.000163	0.00135	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL3—bone cancer	0.000161	0.00133	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—GNA11—bone cancer	0.00016	0.00132	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—IL3—bone cancer	0.000159	0.00132	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—JUN—bone cancer	0.000159	0.00132	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NDUFA12—bone cancer	0.000158	0.00131	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—GNA11—bone cancer	0.000157	0.00131	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—IL3—bone cancer	0.000157	0.0013	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SMO—bone cancer	0.000155	0.00129	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—TP53—bone cancer	0.000155	0.00128	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GRM1—bone cancer	0.000146	0.00121	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL3—bone cancer	0.000145	0.0012	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GRM1—bone cancer	0.000144	0.0012	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL3—bone cancer	0.000143	0.00118	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—GNA11—bone cancer	0.000142	0.00118	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—TP53—bone cancer	0.000139	0.00115	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—TP53—bone cancer	0.000137	0.00114	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—GNA11—bone cancer	0.000133	0.0011	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ATF1—bone cancer	0.000132	0.00109	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—SMO—bone cancer	0.000132	0.00109	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NT5C3A—bone cancer	0.000131	0.00108	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL3—bone cancer	0.000129	0.00107	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RGS1—bone cancer	0.000127	0.00106	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GRM4—bone cancer	0.000127	0.00106	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—GNA11—bone cancer	0.000121	0.000999	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—IL3—bone cancer	0.00012	0.000998	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SMO—bone cancer	0.000115	0.00095	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GRM1—bone cancer	0.00011	0.000916	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TGFBR2—bone cancer	0.00011	0.000913	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL3—bone cancer	0.000109	0.000906	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—TP53—bone cancer	0.000105	0.000871	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GNA11—bone cancer	0.000105	0.000869	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IGF1R—bone cancer	0.000104	0.000859	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SMO—bone cancer	0.000103	0.000855	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SMO—bone cancer	0.000102	0.000844	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ATF1—bone cancer	9.74e-05	0.000808	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL3—bone cancer	9.5e-05	0.000788	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GNA11—bone cancer	9.43e-05	0.000782	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GNA11—bone cancer	9.3e-05	0.000772	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ATF1—bone cancer	8.77e-05	0.000727	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PTGS2—bone cancer	8.68e-05	0.00072	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ATF1—bone cancer	8.65e-05	0.000717	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL3—bone cancer	8.55e-05	0.000709	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL3—bone cancer	8.43e-05	0.0007	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TGFBR2—bone cancer	8.12e-05	0.000674	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SMO—bone cancer	7.78e-05	0.000646	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IGF1R—bone cancer	7.64e-05	0.000634	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KIT—bone cancer	7.51e-05	0.000623	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TGFBR2—bone cancer	7.31e-05	0.000606	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TGFBR2—bone cancer	7.21e-05	0.000598	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GNA11—bone cancer	7.12e-05	0.00059	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—BRAF—bone cancer	7.06e-05	0.000585	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF1R—bone cancer	6.88e-05	0.00057	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—EGFR—bone cancer	6.84e-05	0.000567	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF1R—bone cancer	6.79e-05	0.000563	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ATF1—bone cancer	6.62e-05	0.000549	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL3—bone cancer	6.45e-05	0.000535	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MDM2—bone cancer	5.91e-05	0.00049	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ENO2—bone cancer	5.73e-05	0.000475	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KIT—bone cancer	5.54e-05	0.00046	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TGFBR2—bone cancer	5.52e-05	0.000458	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—DHFR—bone cancer	5.31e-05	0.000441	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—BRAF—bone cancer	5.21e-05	0.000432	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF1R—bone cancer	5.19e-05	0.000431	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—JUN—bone cancer	5.14e-05	0.000426	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—EGFR—bone cancer	5.05e-05	0.000419	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MMP9—bone cancer	5e-05	0.000415	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KIT—bone cancer	4.99e-05	0.000414	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GNA11—bone cancer	4.97e-05	0.000412	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KIT—bone cancer	4.92e-05	0.000408	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—BRAF—bone cancer	4.69e-05	0.000389	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—BRAF—bone cancer	4.63e-05	0.000384	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—EGFR—bone cancer	4.55e-05	0.000377	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP3A4—bone cancer	4.5e-05	0.000373	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—EGFR—bone cancer	4.48e-05	0.000372	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MDM2—bone cancer	4.36e-05	0.000362	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EGFR—bone cancer	4.04e-05	0.000335	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MDM2—bone cancer	3.93e-05	0.000326	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MDM2—bone cancer	3.88e-05	0.000322	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTP1—bone cancer	3.85e-05	0.000319	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—JUN—bone cancer	3.79e-05	0.000315	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KIT—bone cancer	3.77e-05	0.000312	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP9—bone cancer	3.69e-05	0.000306	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—BRAF—bone cancer	3.54e-05	0.000294	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—EGFR—bone cancer	3.43e-05	0.000285	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—JUN—bone cancer	3.42e-05	0.000283	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—bone cancer	3.39e-05	0.000281	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—JUN—bone cancer	3.37e-05	0.000279	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP9—bone cancer	3.32e-05	0.000276	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP9—bone cancer	3.28e-05	0.000272	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGFR—bone cancer	2.98e-05	0.000247	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MDM2—bone cancer	2.97e-05	0.000246	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGFR—bone cancer	2.68e-05	0.000223	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGFR—bone cancer	2.65e-05	0.00022	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JUN—bone cancer	2.58e-05	0.000214	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP9—bone cancer	2.51e-05	0.000208	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—bone cancer	2.5e-05	0.000208	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—bone cancer	2.25e-05	0.000187	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—bone cancer	2.22e-05	0.000184	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGFR—bone cancer	2.03e-05	0.000168	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—bone cancer	1.99e-05	0.000165	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—bone cancer	1.7e-05	0.000141	CbGpPWpGaD
